Dr. Nathan A. Pennell, MD, PhD

Dr. Pennell practices at Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation.

Dr. Pennell's NPI, 1508836438, was assigned on January 24, 2006. Dr. Pennell graduated from University of Florida College of Medicine in 2002. Dr. Pennell holds Ohio license 35091488.

Dr. Pennell's primary practice is Cleveland Clinic Main Campus, at 9500 Euclid Avenue, Cleveland, OH 44195 in Cuyahoga County. The practice phone is (216) 952-9829.

Dr. Pennell's primary practice is Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation. Dmand AI also links Dr. Pennell to 2 clinical labs, each named with a free account. Dr. Pennell's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pennell practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Pennell's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Pennell is licensed in Ohio.

CMS data shows 380 Medicare services from Dr. Pennell across 5 procedure codes in 2024, for 113 Medicare patients. Medicare paid $17,227 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 113 Medicare patients who saw Dr. Pennell in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pennell's median patient age at 68, with 66% women.

In 2024, Dr. Pennell wrote 487 Medicare Part D claims for 72 patients. 67% of them were for generic drugs. CMS names the drug for 285 of them, across 14 drugs with 11 or more claims each, at $946,381 in total drug cost. In 2023, CMS named 235 claims across 10 drugs.

Dmand AI links 116 papers to Dr. Pennell, published from 2009 to 2025. 2022 was the busiest year, with 11. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and ErbB Receptors. Dr. Pennell has published most often in Oncologist. Dr. Pennell's most frequent co-authors are Vamsidhar Velcheti, MD, Pradnya Dinkar Patil, MD and Daniel Philip Raymond, MD.

Dmand AI links Dr. Pennell to 10 clinical trials, 4 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Medullary and Carcinoma, Non-Small-Cell Lung. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 150 general payments to Dr. Pennell from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. AstraZeneca Pharmaceuticals LP paid the most, $51,106. It also lists 3 research payments totaling $687 from 2016 to 2018.

Dr. Pennell graduated from University of Florida College of Medicine in 2002.